Form 8-K · Current Report · Filed 2025-11-12
Halozyme Therapeutics Announces Sale of $1.5 Billion Convertible Senior Notes
Halozyme Therapeutics, Inc. completed the sale of $1.5 billion aggregate principal amount of convertible senior notes due 2031 and 2032 on November 12, 2025. The Company received net proceeds of approximately $1.47 billion after deducting discounts, commissions, and estimated offering expenses. The net proceeds were used to fund capped call transactions, repurchase existing convertible notes, and for general corporate purposes. The convertible notes are unsecured obligations with specific conversion, repurchase, and default terms outlined in the indentures.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001193125-25-277988
- CIK
- 0001159036
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Entry into a Material Definitive Agreement
Creation of a Direct Financial Obligation
Unregistered Sales of Equity Securities
Market reaction
Close before filing
$70.13
Next session
+1.5%
Since filing
+57.2%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.